Additional limitations are those inherent to a retrospective study including lack of standard evaluations and imaging modalities during toceranib treatment, clinically-based evaluation of response to treatment, confirmation of suspect metastatic disease, lack of histopathologic determination of acinar vs. ductal carcinoma, and lack of evaluation for VEGFR expression. This evidence concerns the gene KDR and breast ductal adenocarcinoma.